College of Medicine, Texas A&M University, Dallas, Texas, USA.
Division of Dermatology, Baylor Scott & White, Dallas, Texas, USA.
Dermatol Ther. 2021 Jan;34(1):e14486. doi: 10.1111/dth.14486. Epub 2020 Nov 10.
Ixekizumab is a humanized monoclonal antibody that exhibits its immunomodulatory effects by binding to interleukin 17A (IL-17A), a proinflammatory cytokine. It was approved for the treatment of plaque psoriasis by the Food and Drug Administration in 2016. Ixekizumab has demonstrated superiority in clinical trials against etanercept, with no significant difference in the side effect profile. The chronicity of psoriasis requires continual treatment to achieve disease clearance. Many factors may affect adherence to treatment including patient satisfaction, patient preferences, medication cost, and medication side effects. Limited data on patient adherence, satisfaction, and preference exists in formal literature. Often, surrogate measures must be used to extrapolate information regarding these measures. In this narrative review, we describe patient adherence, satisfaction, and preferences via both direct and surrogate measures as they relate to ixekizumab treatment for moderate-to-severe plaque psoriasis.
依奇珠单抗是一种人源化单克隆抗体，通过与白细胞介素 17A（IL-17A）结合发挥其免疫调节作用，IL-17A 是一种促炎细胞因子。它于 2016 年被美国食品和药物管理局批准用于治疗斑块状银屑病。依奇珠单抗在临床试验中显示出优于依那西普的效果，在副作用谱方面没有显著差异。银屑病的慢性特征需要持续治疗以实现疾病清除。许多因素可能会影响治疗的依从性，包括患者满意度、患者偏好、药物费用和药物副作用。关于患者的依从性、满意度和偏好的有限数据存在于正式文献中。通常，必须使用替代指标来推断这些指标的信息。在这篇叙述性综述中，我们通过直接和替代指标描述了与中重度斑块状银屑病的依奇珠单抗治疗相关的患者依从性、满意度和偏好。
